Parallax Volatility Advisers
MRNA icon

Parallax Volatility Advisers’s Moderna MRNA Stock Holding History

Parallax Volatility Advisers’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.76M Sell
39,458
-8,433
-18% -$436K ﹤0.01% 735
2026
Q1 		$2.6M Buy
47,891
+17,678
+59% +$825K 0.01% 733
2025
Q4 		$891K Sell
30,213
-75,628
-71% -$2.05M ﹤0.01% 1138
2025
Q3 		$2.73M Buy
105,841
+72,149
+214% +$2.01M ﹤0.01% 829
2025
Q2 		$930K Buy
33,692
+20,179
+149% +$531K ﹤0.01% 1074
2025
Q1 		$383K Sell
13,513
-63,523
-82% -$2.25M ﹤0.01% 1234
2024
Q4 		$3.2M Buy
77,036
+10,652
+16% +$509K 0.01% 994
2024
Q3 		$4.44M Buy
+66,384
New +$6.09M 0.01% 841
2024
Q1 		– Sell
-96,046
Closed -$9.68M – 2167
2023
Q4 		$9.55M Buy
96,046
+75,236
+362% +$6.33M 0.02% 601
2023
Q3 		$2.15M Buy
20,810
+15,016
+259% +$1.67M ﹤0.01% 1072
2023
Q2 		$704K Buy
5,794
+5,764
+19,213% +$769K ﹤0.01% 1537
2023
Q1 		$4.61K Sell
30
-30
-50% -$4.95K ﹤0.01% 2489
2022
Q4 		$10.8K Sell
60
-209,940
-100% -$34.3M ﹤0.01% 2560
2022
Q3 		$24.8M Buy
210,000
+161,888
+336% +$24.6M 0.04% 460
2022
Q2 		$6.87M Sell
48,112
-5,700
-11% -$815K 0.01% 855
2022
Q1 		$9.27M Sell
53,812
-54,086
-50% -$9.11M ﹤0.01% 771
2021
Q4 		$27.4M Buy
107,898
+107,870
+385,250% +$31.5M 0.02% 511
2021
Q3 		$11K Hold
28
– – ﹤0.01% 2796
2021
Q2 		$7K Sell
28
-12,641
-100% -$2.26M ﹤0.01% 2790
2021
Q1 		$1.66M Buy
12,669
+6,570
+108% +$952K ﹤0.01% 1837
2020
Q4 		$637K Buy
6,099
+3,240
+113% +$328K ﹤0.01% 2386
2020
Q3 		$202K Buy
+2,859
New +$199K ﹤0.01% 2546
2020
Q2 		– Sell
-131
Closed -$4K – 2811
2020
Q1 		$4K Buy
+131
New +$3.01K ﹤0.01% 2385

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Parallax Volatility Advisers's MRNA Position: Q2 2026 in Review

Parallax Volatility Advisers reduced its Moderna (MRNA) stake by 18% in Q2 2026, selling an estimated $436K and leaving 39,458 shares worth $2.76M. The position accounts for ﹤0.01% of the portfolio, ranked #735.

Parallax Volatility Advisers first reported a position in MRNA in Q1 2020 and has held it in 23 quarters since. The position peaked at $27.4M in Q4 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Parallax Volatility Advisers held 39,458 shares of Moderna worth $2.76M as of Q2 2026.
  • Parallax Volatility Advisers sold 8,433 Moderna shares in Q2 2026, an estimated $436K.
  • Moderna made up ﹤0.01% of Parallax Volatility Advisers's portfolio in Q2 2026, its #735 holding.
  • Parallax Volatility Advisers first reported a position in Moderna in Q1 2020 and has held it in 23 quarters since.
  • Parallax Volatility Advisers's Moderna position peaked at $27.4M in Q4 2021.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Parallax Volatility Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.